Kenvue Shares Drop 7% After Trump Suggests Tylenol Use in Pregnancy May Be Linked to Autism.

Kenvue Shares Drop 7% After Trump Suggests Tylenol Use in Pregnancy May Be Linked to Autism.

Shares of Tylenol maker Kenvue fell about 7% in midday trading following reports that U.S. President Donald Trump plans to link the drug’s use during pregnancy to an alleged risk of autism.

Kenvue, the pharmaceutical company behind the popular pain reliever Tylenol, saw its stock tumble Tuesday after reports emerged that U.S.

President Donald Trump intends to raise concerns over the use of acetaminophen during pregnancy. According to sources, Trump is expected to publicly suggest a link between prenatal Tylenol use and autism, a claim that has generated controversy within the medical community.

The reported remarks add fresh uncertainty for Kenvue, which has already been facing scrutiny over lawsuits alleging health risks associated with its products.

While mainstream medical organizations have stressed that current scientific evidence does not establish a causal connection between

Tylenol use during pregnancy and autism, the President’s expected comments could fuel public debate and influence consumer confidence.

Market analysts note that the sharp sell-off reflects heightened investor anxiety over the potential for reputational damage and regulatory challenges.

Some experts warn that a sustained decline in consumer trust could pressure Kenvue’s long-term growth prospects, despite its strong position in the over-the-counter medicine market.